Company Information
CIN
Status
Date of Incorporation
04 January 1995
State / ROC
Chandigarh / ROC Chandigarh
Last Balance Sheet
31 March 2023
Last Annual Meeting
30 September 2023
Paid Up Capital
590,868,600
Authorised Capital
600,000,000
Directors
Rajinder Kumar Gupta
Director/Designated Partner
about 2 years ago
about 2 years ago
Navrattan Munjal
Director/Designated Partner
over 2 years ago
over 2 years ago
Himanshu Jain
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Neerja Chathley
Director/Designated Partner
about 6 years ago
about 6 years ago
Sri Prakash Sharma
Director/Designated Partner
about 8 years ago
about 8 years ago
Pradeep Kumar
Director
about 10 years ago
about 10 years ago
Tara Sankar Bhattacharya
Director
about 12 years ago
about 12 years ago
Pardeep Verma
Manager/Secretary
over 26 years ago
over 26 years ago
Past Directors
Ashwani Kumar Vig
Additional Director
almost 6 years ago
almost 6 years ago
Sahil Munjal
Additional Director
almost 6 years ago
almost 6 years ago
Jagvir Singh Ahluwalia
Additional Director
over 7 years ago
over 7 years ago
Poonam Maini
Additional Director
over 7 years ago
over 7 years ago
Prabhat Khurana
Director
about 10 years ago
about 10 years ago
Narinder Kumar Bansal
Cfo(kmp)
over 11 years ago
over 11 years ago
Vinay Arora
Additional Director
over 11 years ago
over 11 years ago
Satyendra Vikram Singh
Nominee Director
over 12 years ago
over 12 years ago
Rishav Mehta
Additional Director
over 15 years ago
over 15 years ago
Harmander Pal Singh Chawla
Additional Director
over 16 years ago
over 16 years ago
Kotakkatteri Maruvote Sreedharan Nambiar
Director
about 24 years ago
about 24 years ago
Jatendar Kumar Kakkar
Director
almost 29 years ago
almost 29 years ago
Vikrant Rai Mehta
Director
almost 31 years ago
almost 31 years ago
Sanjeev Rai Mehta
Director
almost 31 years ago
almost 31 years ago
Gopal Munjal
Director
almost 31 years ago
almost 31 years ago
Patents
The present invention relates to an improved and industrially advantageous process for the preparation of imatinib of formula I,
or its mesylate salt with controlled level of genotoxic impurity of formula II,
a key intermediate for imatinib.
The present invention relates an improved and cost-effective, industrially advantageous process for the preparation of pure aripiprazole, wherein concerned impurity i.e. corresponding quinoline impurity, namely 7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)quinolin-2(1H)-one is reduced to an amount of less than...
The present invention relates to a cost effective, environment friendly industrially viable process for the preparation of 7,8-dimethoxy-1,3-dihydro-2H-3-benzazepine-2-one, an intermediate used in the preparation of ivabradine, without using acid chloride intermediate and condensing agent
ABSTRACT
"AN INDUSTRIAL PROCESS FOR THE PREPARATION OF 5-BROMO-2-FLUOROBENZONITRILE"
The present invention provides an industrially advantageous process for the preparation of pure 5-bromo-2-fluorobenzonitrile, a precursor of key intermediates used in the synthesis of certain xanthine oxidase inhibitor compoun...
ABSTRACT
“AN IMPROVED PROCESS FOR THE PREPARATION OF CLARITHROMYCIN BY SELECTIVE METHYLATION""
The present invention relates to a commercially viable and industrial advantageous process for preparation of clarithromycin via selective methylation of a hydroxy group at 6 position of erythromycin A derivative ...
The present invention provides a process for the preparation of 1-phenyl-3-dimethylaminopropane derivatives of formula I,
and its pharmaceutically acceptable salts thereof from intermediate of formula II,
wherein R1 can be selected from -OR2, halo, -CH2OR2, -SR2, -SOR2, -SO2R2, SO3H, -NO2, -NR2R2", -CONR2R2", carb...
The present invention provides an industrially advantageous process for the preparation of pure allyl protected keto derivative of formula I, an intermediate of ezetimibe.
Formula-I
by using a novel O-allyl amide derivative of formula II.
Formula-II
wherein R is methyl or ethyl
...
The present invention relates to a commercially viable and improved process for
preparation of tapentadol of formula I and its pharmaceutically acceptable salts,
via novel intermediates tertiary hydroxy protected sulfonyl compound of formula
III.
wherein Rj is selected from hydrogen, straight chain or branched a...
ABSTRACT
“A PROCESS FOR PREPARING AN INDOLINE DERIVATIVE”
The present invention provides an improved, cost-effective and commercially viable process for preparing an indoline derivative of formula I, a key intermediate used in the synthesis of silodosin, through novel intermediates.
Formula I
...
The present invention relates to a process for preparing pure olmesartan medoxomil of formula I,
particularly, the present invention provides a process for preparing pure olmesartan medoxomil by detritylation of trityl olmesartan medoxomil.
"AN IMPROVED PROCESS FOR PREPARING PURE MINODRONIC ACID AND INTERMEDIATES THEREOF"
ABSTRACT:
The present invention relates to an industrially advantageous, cost-effective, and reproducible process for preparation of pure minodronic acid, including salts, hydrates and polymorphs thereof, by using ecofriendly proc...
The present invention provides an improved process for the preparation of highly
pure bexarotene of formula I.
The present invention also provides impurities of bexarotene, method of isolation and
identification of these impurities, and use of these impurities as reference marker as well as reference standard.
...
The present invention provides a process for preparing pure argatroban of formula I,
having reduced level of impurities by optimizing the reaction conditions of different
stages.
The present invention also provides novel impurities of argatroban and methods of
identifying as well quantifying impurities.
...
The present invention relates to a novel and industrially advantageous process for the preparation of 5-substsituted indole derivative, particularly it relates to process for the preparation of 5-bromo-3-[(R)-l-methyl-pyrrolidin-2-ylmethyl]-lH-indol of formula I,
a key intermediate for the synthesis of eletriptan o...
The present invention provides an effective and industrially advantageous process for purification of 2-(2-(3-(S)-(3-(7-chloro-2-quinolinyl)- ethenyl)-phenyl)-3-(hydroxy-propyl)phenyl-2-propanol of formula I,
Formula I
which is a key intermediate for the synthesis of montelukast or pharmaceutically acceptable ...
The present invention relates to an industrially advantageous process for the preparation of α form of imatinib mesylate, an inhibitor of tyrosine kinases, having residual solvents with in specified limits as per ICH guidelines.
The present invention provides a process for preparing pure rosuvastatin of formula I,
or pharmaceutically acceptable salts thereof through rosuvastatin 1-(1-naphthyl)ethylamine salt of formula II,
wherein wavy line (~) represent (R), (S) stereochemistry or racemate thereof.
The present invention relates to an improved and industrially advantageous process for preparation of eletriptan of formula I,
or pharmaceutically acceptable salts thereof from bromo indole intermediate of formula II,
through isolation of N-acetylated bromo indole intermediate of formula III,
to elude carrying ...
ABSTRACT
“Process for the preparation of Silodosin through Novel Salt of Cyano Hydroxy Intermediate.”
The present invention provides an improved and efficient process for the preparation of silodosin of formula I and pharmaceutically acceptable salts thereof
Formula I
through novel tartrate salt of...
The present invention provides an improved, efficient, safe and convenient process for preparation of lisdexamphetamine and its pharmaceutically acceptable salts by using novel mixed anhydride intermediate. The present invention also provides a process for preparation of diamino protected amide compound namely BOC p...
The present invention relates to a novel polymorphic form I of rifaximin and process for preparation thereof. The novel polymorphic form I is characterized by powder x-ray diffraction pattern at 20, 5.2, 7.2, 8.4 and 8.7 degrees ±0.2 and water content within the range of 2.0 to 4.5%. The invention further provides p...
ABSTRACT
PROCESS FOR PURIFICATION OF 4,5-DIMETHOXY BENZOCYCLO- BUTANE DERIVATIVES
The present invention relates to an efficient and industrially advantageous process for purification of 4,5-dimethoxy benzocyclobutane derivatives, which are important key intermediates in the preparation of ivabradine hydrochlo...
The present invention relates to an industrially advantageous and improved process for preparation of dabigatran etexilate of formula I and its pharmaceutically acceptable salts.
ABSTRACT OF THE INVENTION
Process for the preparation of pure Form B of Tapentadol Hydrochloride
The present invention relates to an improved and industrially advantageous process for the preparation of pure Form B of tapentadol hydrochloride in consistent manner by treating tapentadol base with a suitable so...
The present invention provides an industrially advantageous, economical and improved process for preparation of minodronic acid including salts and hydrates thereof. The present invention also provides a process for the preparation of key intermediates of minodronic acid in high yield and high purity.
...
ABSTRACT OF THE INVENTION
“Process for the preparation of rosuvastatin via novel intermediates.”
The present invention provides an industrially advantageous and cost-effective process for preparation of rosuvastatin of formula I or pharmaceutically acceptable salts thereof,
Formula I
via novel inte...
The present invention relates to a process for the preparation of phenyl carbamate derivative of formula I, a key intermediate for the synthesis of quetiapine, by condensing 2-amino diphenyl sulfide with phenyl chloroformate in the absence of an organic solvent.
The present invention relates to an industrially advantageous and efficient process for the preparation of raltegravir potassium Form 3 from raltegravir by using potassium base and alcoholic solvent.
The present invention relates to an efficient and industrially advantageous process
for preparation of 3-(2-bromo-4,5-dimethoxybenzene)propionitrile of formula I,
with high purity and high yield,wherein compound of formula I is an important precursor of 1-cyano-4,5-
dimethoxybenzocyclobutane, a key intermediate i...
The present invention relates to an improved and industrially advantageous process for the preparation of pure tapentadol hydrochloride Form B in consistent manner.
The present invention provides an improved process for the preparation of sunitinib of formula I,
and its pharmaceutically acceptable salts thereof.
Further, present invention also provides process for the preparation of form I of
sunitinib malate.
The present invention provides an industrially advantageous process for the preparation of rosuvastatin of formula I,
or pharmaceutically acceptable salts thereof.
The present invention relates to an industrially advantageous process for the preparation of 0-desmethyl-venlafaxine, a venlafaxine metabolite, and pharmaceutically acceptable salts thereof by demethylating venlalaxme or salts theroi" using an alkali or alkaline earth metal salts of mercapto acids and their derivati...
The present invention relates to highly pure Ropinirole or salt thereof and a process for preparing highly pure Ropinirole of structural Formula I,
by reducing nitro compound of formula II,
With hydrogen gas in the presence of a catalysts in water to produce amino compound and cyclizing the resulting amino compou...
The present invention provides a process for the preparation of montelukast sodium through novel montelukast amine salt of formula I,
wherein (R)2NH is selected from l-(l-naphthyl)ethylamine, S-methyl-L-cysteine, diallylamine or isomers thereof.
The present invention relates to process for the preparation aripiprazole polymorph having an average particle size less than 100 µm using a specific solvent system and reaction condition for inducing precipitation.
The present invention provides an industrially advantageous process for the preparation of highly pure prulifloxacin of formula I and its pharmaceutically acceptable salts.
The present invention also provides a novel process for the purification of prulitloxacin acid addition salt.
The present invention relates to an improved process for synthesizing highly pure nateglinide form B. More particularly, the present invention relates to the process for synthesizing highly pure nateglinide form B directly from nateglinide alkyl ester derivative. The present invention also relates to process for con...
The object of the present invention encompasses amorphous rimonabant and processes thereof. Another object of the present invention encompasses processes for converting crystalline form of rimonabant to amorphous rimonabant.
The present invention relates to an industrially advantageous process for the preparation of ezetimibe of formula I in high yields
by using novel benzyl ester intermediates.
The present invention relates to the preparation of highly pure donepezil of Formula I
or salt thereof,by hydrogenating indanonylidenyl compound of
using platinum catalysts.
The present invention relates to an industrial process for the preparation of highly pure 2-[4-(4-choloro-butyryl) phenyl]-2-methyl propanol, a key intermediate in the preparation of Fexofenadine, from methyl 2-[4-(4-choloro-butyryl) phenyl]-2-methyl propanoate in presence of anhydrous alcoholic- hydrogen chloride.
...
The present invention relates to a process for the preparation of highly pure atomoxetine of formula I and pharmaceutically acceptable salts thereof
The present invention also aims at novel processes for the preparation and purification of intermediates involved in the process of the present invention.
...
The invention encompasses amorphous ivabradine hydrochloride and its method of preparation thereof. An improved process for the preparation of crystalline ivabradine hydrochloride is also provided..
The present invention relates to an industrially advantageous process for the preparation of tetrahydrofuran antifungals preferably posaconazole of formula I.
The present invention further relates to improved processes for preparing key intermediates useful in the preparation of posaconazole.
The present invention relates to highly pure Ropinirole or salt thereof and a process for preparing highly pure Ropinirole of structural Formula I,
Formula I by reducing nitro compound of formula II,
Formula II
and cyclizing the resulting amino compound in situ using palladium on carbon in the presence of aqueous...
The present invention relates to an industrially advantageous process of making hisphosphonic acid or its salt in particular risedronic acid, [l-hydroxy-2(3-pyridinyl)ethylidene] his phosphonic acid, having Formula-I or its salts in high purity and high yields
The present invention provides an improved process for the preparation of temozolomide of formula I,
by employing the mild reaction condition.
The present invention relates to an industrial process for the preparation of highly pure 2-[4-(4-choloro-butyryl) phenyl]-2-methyl propionic acid of Formula 1,
a key intermediate in the preparation of Fexofenadine, by purifying with cyclohexane.
The present invention relates to an improved process for the preparation of
bibenzimidazole derivative, particularly 4-methyl-6-( 1 -methyl
benzimidazole-2-yl)-2-n-propylbenzimidazole of fomiula I,
a key intermediate in the preparation of telmisartan.
The present invention provides to an improved process for the preparation of O-desmethyl-venlafaxine of formula I,
by demethylating venlafaxine or its pharmaceutically acceptable salts thereof by using alkali metal sulphide under mild reaction conditions.
The present invention relates to anhydrous 3-(acetylamino)-l-propanesulfonic acid calcium salt (acamprosate calcium) of formula I and process of its preparation thereof.
The present invention relates to an industrially advantageous method for the purification of anastrozole of Formula I.
Formula I wherein isoanastrozole of Formula VI.
Formula VI present in crude anastrozole as an impurity, is removed by using gel purification.
The present invention provides a cost effective and industrially advantageous process for the preparation of ranolazine of formula I,
Formula I
by reacting 2,6-dimethylaniline derivative with chloroacetyl chloride in the presence of base in water optionally with water miscible solvent and resulting amide intermedi...
This invention provides a process for the preparation of highly pure duloxetine hydrochloride of formula I,
from duloxetine free base via its acid addition salts.
The invention also aims at providing a process for the purification of duloxetine hydrochloride, wherein the level of unwanted R-enantiomer is red...
The present invention provides a process for the preparation of indole derivatives, specifically N-methyl-1H-indole-5-ethanesulfonamide of formula I,
involving novel intermediate, which is used as key intermediate for the synthesis of naratriptan of formula II,
and its pharmaceutically acceptable salts thereof hig...
The present invention relates to novel process for the preparation of amorphous form of Clopidogrel hydrogen sulfate of the formula I from clopidogrel base by using a mixture of ketonic and halogenated solvent.
The present invention relates to the preparation of amorphous atorvastatin calcium of formula I,(Formula Removed)
from (3R, 5R) tert.-butyl (6-{2-[3-phenyl-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-(l-methylethyl)-pyrrol-l-yl]-ethyl }-2,2-dimethyl {l,3-}dioxan-4-yl) acetate of formula II.
The present invention relates to an industrially advantageous process for the preparation of imatinib of formula I,
and its pharmaceutically acceptable salt, specifically imatinib mesylate.
The present invention relates to an improved process for the preparation of erythromycin A 9-oxime, a key intermediate in the preparation of clarithromycin, roxithromycin and azithromycin, directly from erythromycin thiocyanic acid salt using organic base in alcoholic solvent without isolating erythromycin A .
...
The present invention relates to novel crystalline forms of cinacalcet hydrochloride, a well known calcimimetic agent, and processes for preparing the same.
The present invention relates to an industrially advantageous, eco-friendly process for the preparation of rimonabant of formula-I,
(Figure Remove)
Formula-I
staring from 1 -(4-chlorophenyl)-propan-1 -one in high yields and high purity by using mild reaction conditions and avoiding use of toxic and expensive reag...
The present invention relates to an improved process for synthesizing highly pure nateglinide form H. More particularly, the present invention relates to the process for synthesizing highly pure nateglinide form H directly from nateglinide alkyl ester derivative.
The present invention relates to a process for the preparation and purification of N-methyl-2-(4-hydrazino-phenyl) ethane sulfonamide hydrochloride of formula I,
a key intermediate in the preparation of naratriptan and its pharmaceutically acceptable salts, using a source of hydrochloric acid or a solvent to enhanc...
The present invention relates to a novel process for the preparation of indole
derivatives. In particular, present invention relates to the process for preparing
naratriptan of formula I, and its salts using novel intermediates.
The present invention relates to an efficient and cost-effective process for the
preparation of 6-methylenandrost-l,4-diene-3,17-dione (exemestane) by
dehydrogenation of 6-methylenandrost-4-ene-3,17-dione using an dehydrogenating agent in the presence of an acid catalyst and at least one co-oxidant in an org...
The present invention provides an improved, industrial advantageous process for the preparation of gefitinib of formula I,
and its pharmaceutically acceptable salts thereof in high yield and purity.
The present invention relates to an improved process for the preparation of 6-0-methylerythromycin A derivatives, intermediates of clarithromycin, by selective methylation of erythromycin A derivative in a mixture of a acyclic or cyclic alkanes having C6-C10 carbon atoms, and a polar aprotic solvent using a methylat...
The present invention provides an industrially advantageous process for the preparation of highly pure prulifloxacin of formula I and its pharmaceutically acceptable salts.The present invention also provides a novel process for the purification of prulifloxacin acid addition salt.
The present invention provides a process for the purification of cinacaicet hydrochloride by employing washing with aqueous solution or aqueous solution of suitable acid or slurry wash in a solvent or solvent mixture.
The present invention provides a process for the purification of cinacaicet by gel purification to...
The present invention relates to the preparation of amorphous atorvastatin hemicalcium of formula I,
from (4R-cis)-(6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(l-
methylethyl)-pyrrol-l -yl]-ethyl]-2,2-dimethyl-[ 1,3]-dioxan-4-yl-acetic acid
tertiary-butyl ester of formula II.
...
The present invention relates to an industrially advantageous process for the purification of ezetimibe of formula I
Specifically, the present invention relates to a process for the synthesis of enantiomerically and chemically pure ezetimibe which is substantially free of impurities.
The present invention relates to an improved process for synthesizing highly pure nateglinide form H. More particularly, the present invention relates to the process for synthesizing highly pure nateglinide form H directly from nateglinide alkyl ester derivative.
The present invention relates to an improved process for the preparation of 6-0-methylerythromycin A derivatives, intermediates of clarithromycin, by selective methylation of erythromycin A derivative in a mixture of a acyclic or cyclic alkanes having C6-C10 carbon atoms, and a polar aprotic solvent using a methylat...
The present invention relates to a novel and industrially advantageous process for the preparation of highly pure anhydrous Fexofenadine hydrochloride directly from fexofenadine base without isolating hydrous Fexofenadine hydrochloride.
The present invention provides an eco-friendly and cost-effective process for the preparation of piperidine derivative of formula I,
a key intermediate useful for the synthesis of fexofenadine and its pharmaceutically acceptable salts thereof.
The present invention relates to pure Venlafaxine or salt thereof and a process for preparing highly pure Venlafaxine of structural Formula I,
from N,N-didesmethyl venlafaxine or salt thereof of formula II,
in the presence of hexamethylenetetramine.
The present invention relates to highly pure Venlafaxine or salt thereof and a process for preparing highly pure Venlafaxine of structural Formula I or salt thereof,
by double methylation of N,N-didesmethyl venlafaxine or salt thereof using formaldehyde and formic acid in the presence of organic base.
...
The present invention provides an improved process for the preparation of ranolazine of formula I and pharmaceutically acceptable salts thereof,
by reacting 2,6-dimethylaniline derivative with chloroacetyl chloride in the presence of base in water and resulting amide intermediate is reacted with piperazine and the ...
The present invention relates to an industrially advantageous process for the preparation of tetrahydrofuran antifungals preferably posaconazole of formula I.
The present invention further relates to improved processes for preparing compound of formula II,
a key intermediate in the preparation of posaconazole.
...
The present invention relates to an industrially advantageous process for the preparation of thiazolidine derivatives, such as pioglitazone of formula 1 and its pharmaceutically acceptable salts.
This invention also provides novel synthetic intermediates useful in the process for the preparation of pioglitazone.
...
The present invention relates to an industrially advantageous and high throughput process for the preparation of imidazole-4,5-dicarboxylate derivative, particularly dialkyl-2-propylimidazole-4,5-dicarboxylate of formula I,
wherein R represents a straight-chained or branched C1-C4 alkyl group
a key intermediate in...
The present invention relates to an improved and industrially advantageous process
for preparation of moxifloxacin hydrochloride of formula I.
The present invention provides novel acid addition salts of ivabradine of formula I,
including their hydrates, solvates, anhydrous form, and non solvated form, both in amorphous and crystalline forms.
The present invention relates to an industrially advantageous process for the preparation of 2-phenyl-3-aroylbenzothiophenes, specifically raloxifene of formula I or a pharmaceutically acceptable salt thereof.
The present invention provides an improved and industrially advantageous process for the preparation of temozolomide of formula I.
by filtration or centrifugation; thus avoiding extraction of temozolomide from reaction mixture using large volumes of solvent.
The present invention provides an industrially advantageous and efficient process for the preparation of colesevelam hydrochloride using dried colesevelam and a source of chloride ion.
The present invention provides an efficient and industrially advantageous process for the preparation of ezetimibe of formula I, using novel intermediates.
The present invention provides a novel process for preparing cinacalcet of formula I,
and pharmaceutically acceptable salts thereof.
The present invention also provides novel nitrogen protected synthetic intermediates
useful in the process of the present invention.
The present invention encompasses a process for the preparation of highly pure amorphous ivabradine hydrochloride by hydrolyzing acid addition salt of ivabradine with a suitable base, and treating ivabradine with alcoholic hydrogen chloride to get highly pure amorphous ivabradine hydrochloride.
...
The present invention provides a process for the preparing l-phenyl-3-dimethylaminopropane derivatives of formula I,
and its pharmaceutically acceptable salts thereof via novel intermediates.
The present invention provides a process for the preparation of androstenone derivatives; specifically 3-oxo-4-aza-5 alpha-androstene-17ß-carboxylic acid of formula I,
a key intermediate for dutasteride.
The present invention relates to an isolated impurity of rimonabant, referred to as "Bis impurity" and removal thereof.
A process for the preparation of (S)-pregabalin of formula I containing cyanide ion content less than 5 ppm or free from the cyanide ion,
by extracting its cyano diester intermediate of formula III,
wherein R1 and R2 are the same or different and are hydrogen, C1-C6 alky I, aryl, benzyl, substituted benzyl, or C...
The present invention provides a process for the preparation of amorphous fexofenadine hydrochloride from fexofenadine via its weak acid addition salt.
The present invention further provides a process for the preparation of amorphous fexofenadine hydrochloride from fexofenadine acid addition salt.
...
The present invention relates to an improved process for the preparation of pure 2-nitro-6-(2-di-n-propylaminoethyl)-phenylacetic acid of formula I or its salts in high yields, an intermediate in the preparation of an indolone derivative namely Ropinirple of Formula II,
“Process for the preparation of highly pure fesoterodine fumarate”
The present invention relates to an improved and industrially advantageous process for the preparation of highly pure fesoterodine fumarate having assay in range 98 to 102% w/w and acceptable fumaric acid content, using a suitable crystallization ...
The present invention relates to an improved and industrially advantageous process for preparing pure tapentadol hydrochloride Form B in consistent manner.
The present invention relates to a novel process for the preparation of Form I of Clopidogrel hydrogen sulfate, namely methyl (+)-(S)-α-(o-chlorophenyl)-6,7-dihydrothieno [3,2-c] pyridine-5(4H)-acetate hydrogen sulfate of formula I.
INTERMEDIATES USEFUL FOR THE PREPARATION OF ANTIHISTAMINIC PIPERIDINE DERIVATIVE
The present invention relates to an industrially advantageous process for the preparation of highly pure a-ethyl-4-hydroxydesoxybenzoin of Formula-I, a key intermediate in the preparation of tamoxifen, useful in the treatment of breast cancer.
The present invention relates to a novel process for preparing amine derivatives of formula I, as calcimimetics,
wherein Ar/ or Ar2 is either naphthyl or phenyl optionally substituted with 0 to 5 substituents each independently selected from the group consisting of lower alkyl, halogen, lower alkoxy, lower thioalky...
The present invention relates to novel crystalline form-Ill of 5-(4-chlorophenyl)-l-(2,4-dichlorophenyl)-4-methyl-A piperidin-l-yl)pyrazole-3-carboxamide namely rimonabant of formula-I,processes for its preparation and conversion to form-I of rimonabant.
"AN IMPROVED PROCESS FOR PREPARATION OF PURE POLYMORPHIC FORM GAMMA OF SILODOSIN"
The present invention provides an improved and industrially advantageous process for preparation of pure polymorphic form gamma (?) of silodosin. More particularly, present invention relates to pure polymorphic form gamma (?) of sil...
The present invention provides an improved efficient safe and convenient process for preparation of highly pure deferasirox. The present invention also provides a novel process for purification of deferasirox by using quaternary ammonium hydroxides as a base.
ABSTRACT
"AN INDUSTRIAL PROCESS FOR PREPARATION OF PHENYL PROPANOL DERIVATIVE"
The present invention relates to an industrially advantageneous, cost effective, operationally safe method for the preparation of a phenyl propanol derivative of formula I,
Formula I
an important intermediate in prepara...
The present invention provides a process for the preparation of 1-phenyl-3-dimethylaminopropane derivatives of formula I,
and its pharmaceutically acceptable salts thereof from cyano intermediate of formula
wherein R1 can be selected from -OR2, halo, -CH2OR2, -SR2, -SOR2, -SO2R2, -SO3H, -NO2, -NR2R2", -CONR2R2", c...
The present invention relates to an improved and industrially advantageous process for the preparation of pure nateglinide form H in consistence manner directly from nateglinide alkyl ester. In particular, the present invention provides an improved and industrially advantageous process for the preparation of pure na...
The present invention relates to a novel process for the preparation of fesoterodine of formula I and pharmaceutically acceptable salts thereof,
Formula I
via novel hydroxy carbonitrile intermediate of formula II;
Formula II
a novel process for the preparation of novel hydroxy carbonitr...
The present invention relates to an efficient and industrially advantageous process for the preparation of pure 1H-pyrazolo[3,4-d] pyrimidine derivative. In particular the present invention provides a process for the preparation of pure 4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d] pyrimidine, a key intermediate of...
A process for the purification of cinacalcet hydrochloride of formula I,
Formula I
to reduce the level of genotoxic impurities in cinacalcet hydrochloride by using a suitable solvent system.
The present invention provides a novel and an industrially advantageous process for the preparation of pure metaraminol or salts thereof. In particular, the present invention provides an industrially advantageous process for the preparation of enantiomerically pure metaraminol bitartrate of formula I
Formula I N...
The present invention provides a novel and an industrially advantageous process for the preparation of pure metaraminol or salts thereof. In particular, the present invention provides an industrially advantageous process for the preparation of enantiomerically pure metaraminol bitartrate of formula I
...
The present invention provides an efficient and industrially advantageous process for purification of N-methyl-2-chloropyrimidine derivative, namely N-(2-chloropyrimidin-4-yl)-N,2,3-trimethyl-2H-indazol-6-amine of formula I,
Formula I
which is a key intermediate of pazopanib hydrochloride.
The present invention a...
The present invention relates to an efficient and industrially advantageous process for purification of 4,5-dimethoxy benzocyclobutane derivatives, which are important key intermediates in the preparation of ivabradine hydrochloride.
The present invention relates to an efficient and industrially advantageous process for preparation of 5,6-dimethoxy-1-indanone of formula I, which is a key intermediate of donepezil hydrochloride, with improved yield, starting from 3-chloro-3',4'-dimethoxypropiophenone.
The present invention provides an improved process for the preparation of highly pure 2-(4-[l -hydroxy-4-[4-(hydroxy-diphenyl-methyl)piperidin-1 -yl]-butyl} -phenyl)-2-methyl-propionic acid (fexofenadine) of Formula I, or its salts thereof
The present invention relates to an improved, efficient, and industrially advantageous process for preparation of dipeptidyl peptidase-4 (DPP-4) inhibitor, saxaghptin monohydrate of formula I.
A1-
on
.][sO Formula (T)
Particularly, the present invention provides an improved process for the preparation of saxaghp...
The present invention relates to an improved, efficient, and industrially advantageous process for the preparation of Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib of formula I and its key intermediates.
Particularly, the present invention provides a novel intermediates and process for the purification.
M...
The present invention relates to an improved, efficient, and industrially advantageous process for preparation of solid forms of Bruton's Tyrosine Kinase (BTK) inhibitor, Ibrutinib of formula I.
Particularly, the present invention provides process for the preparation of Crystalline Form A and Crystalline Form C ...
The present invention relates to process for the preparation of Atorvastatin of formula I, and intermediates thereof.
Particularly, the present invention relates to an improved, efficient, and industrially advantageous process for the preparation of key intermediate, 2-[2-(4-Fluorophenyl)-2-oxo-1-phenylethyl]-4-...
The present invention relates to crystalline ivabradine hydrochloride of formula I and process for the preparation thereof.
Particularly, the present invention relates to process for the preparation of crystalline ivabradine hydrochloride.
ABSTRACT
An improved process for preparing highly pure donepezil hydrochloride
The present invention relates to a process for preparing highly pure donepezil hydrochloride from 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-ylidenyl]methyl piperidine or acid addition salts thereof.
Further the present invention rela...
ABSTRACT
Crystalline salts of lisdexamfetamine
The present invention relates to salts of pure amphetamine prodrug, in particular, L-lysine-d-amphetamine (known as lisdexamfetamine) and industrial advantageous process for preparation thereof.
Further the present invention relates to the crystalline salts of lisd...
The present invention relates to an improved cost-effective process for preparing
5 eltrombopag olamine and its key intermediates.
Further, the present invention provides an improved process for the preparation of
compound of Formula IVa, an important starting intermediate of eltrombopag or
eltrombopag olamine. ...
The present invention relates to an eco-friendly and efficient process for preparing mirabegron and its key intermediate.
In a particular aspect of present invention relates to an improved process for the preparation of compound of formula 2 i.e. (2R)-2-hydroxy-N-[2-nitrophenyl) ethyl]-2-phenylacetamide or its salt...
The present invention is to provide an efficient process for preparing bempedoic acid of Formula 1 wherein by-product such as 4-methylbenzene sulfinic acid of Formula 6 is not carried forward to effluent and upcycling the compound of Formula 6 for preparing TosMIC. Further, the present invention provide an efficie...
The present invention provides an eco-friendly and efficient process for preparing bempedoic acid; wherein the process uses enzymatic transformations and/or a combination of chemical reactions at hydrolysis and reduction steps. The enzymatic or chemo-enzymatic reactions used in the process of the present inventi...
The present invention provides an economical process for preparing pure pentazocine and/or pharmaceutically acceptable salts thereof.
Further, the present invention provides an improved process for the preparation of crystalline acid addition salt of pentazocine and its conversion to pure pentazocine of Form...
Charges
21 June 2019
Idbi Trusteeship Services Limited
808 Crore
05 September 2018
Vistra Itcl (india) Limited
424 Crore
05 September 2018
Vistra Itcl (india) Limited
75 Crore
04 March 2013
State Bank Of India
1,171 Crore
04 January 2012
Asset Reconstruction Company (india) Limited
30 Crore
24 November 2011
Edelweiss Asset Reconstruction Company Limited
40 Crore
03 October 2011
Bank Of India
50 Crore
30 June 2011
Canara Bank
25 Crore
24 March 2011
Edelweiss Asset Reconstruction Company Limited
30 Crore
13 November 2010
Edelweiss Asset Reconstruction Company Limited
50 Crore
13 October 2010
Icici Bank Limited
12 Crore
04 May 2010
Edelweiss Asset Reconstruction Company Limited
30 Crore
04 March 2010
Bank Of India
22 Crore
11 December 2009
Edelweiss Asset Reconstruction Company Limited
15 Crore
30 October 2009
Asset Reconstruction Company (india) Limited
12 Crore
25 August 2009
Deg - Deutsche Investitions-und Entwicklungsgesellschaft Mbh
95 Crore
19 August 2009
Idbi Trusteeship Services Ltd.
15 Crore
06 August 2009
Edelweiss Asset Reconstruction Company Limited
50 Crore
16 June 2009
Edelweiss Asset Reconstruction Company Limited
20 Crore
10 June 2009
Idbi Bank Limited
45 Crore
19 June 2008
Bank Of India
25 Crore
19 June 2008
Bank Of India
15 Crore
01 May 2008
Edelweiss Asset Reconstruction Company Limited
15 Crore
24 October 2007
Technology Development Board
10 Crore
28 September 2004
Technology Devlopment Board
1 Crore
27 September 2002
Bank Of India
2 Crore
25 November 2010
Bank Of Baroda
91 Crore
01 July 2010
L & T Finance Limited
10 Crore
09 May 2011
L & T Finance Limited
20 Crore
10 January 2011
Phoenix Arc Private Limited
35 Crore
13 August 2008
Phoenix Arc Private Limited
15 Crore
16 July 2009
Phoenix Arc Private Limited
20 Crore
22 August 2002
State Bank Of Patiala
1 Crore
25 May 2011
Sbi Global Factors Limited
10 Crore
06 January 2000
Consortium Sbi Sbop Bank Of India
79 Crore
11 September 2008
State Bank Of India
20 Crore
29 June 2010
State Bank Of Patiala
30 Crore
27 October 2005
State Bank Of India
30 Crore
22 November 2010
State Bank Of Patiala
15 Crore
02 September 2009
State Bank Of Indore
20 Crore
26 September 2007
State Bank Of Patiala
15 Crore
25 May 2011
State Bank Of Patiala
50 Crore
23 March 1999
State Bank Of Patiala
25 Crore
04 February 2000
State Bank Of India
543 Crore
23 March 1999
State Bank Of Patiala
90 Crore
10 October 2000
State Bank Of India
399 Crore
17 April 2013
Mahindra And Mahindra Financial Services Limited
25 Crore
31 March 2012
Siemens Financial Services Private Limited
5 Crore
28 September 2011
Indiabulls Housing Finance Limited
3 Crore
28 June 2007
The Catholic Syrian Bank Limited
10 Crore
24 February 2010
The Catholic Syrian Bank Limited
15 Crore
06 August 2001
Industrial Development Bank Of India
5 Crore
31 July 2008
The Bank Of Rajasthan Limited
10 Crore
21 February 2011
Religare Finvest Limited
2 Crore
16 June 2007
Barclays Bank Plc
10 Crore
16 June 2007
Barclays Bank Plc
10 Crore
07 June 2012
Export - Import Bank Of India
45 Crore
28 September 2007
Idbi Bank Limited
10 Crore
27 August 2011
Reliance Capital Ltd
19 Crore
31 July 2008
State Bank Of Hyderabad
10 Crore
17 October 2006
Abn Amro Bank N. V.
18 Crore
14 March 2006
Standard Chartered Bank (being The Security Agent Acting On Behalf Of And For
18 Crore
28 March 2006
Export Import Bank Of India
17 Crore
22 January 2005
The South Indian Bank Limited
5 Crore
14 March 2006
State Bank Of India
20 Crore
02 December 2005
Bank Of Rajasthan Limited
10 Crore
28 October 2005
State Bank Of Patiala
15 Crore
27 January 2005
Bank Of India
8 Crore
19 February 2010
Sicom Limited
20 Crore
28 May 2005
Axis Bank Limited
15 Crore
26 November 2008
Idbi Bank Limited
10 Crore
27 June 2005
Industrial Development Bank Of India Limited
14 Crore
15 January 2005
Export-import Bank Of India
16 Crore
10 March 2007
State Bank Of Indore
10 Crore
07 January 2005
The Cathloic Syrian Bank Ltd.
12 Lak
21 October 2004
State Bank Of India
30 Crore
31 December 2004
Axis Bank Limited
5 Crore
27 January 2005
Bank Of India
10 Crore
17 June 2006
Bank Of India
10 Crore
31 December 2004
Uti Bank Ltd.
5 Crore
04 July 2008
State Bank Of Patiala
6 Crore
05 October 2004
State Bank Of Patiala
10 Crore
24 December 2003
Export Import Bank Of India
12 Lak
11 March 2004
Uti Bank Ltd..
5 Crore
18 March 1998
Industrial Development Corporation Of India
1 Crore
03 March 2003
State Bank Of India
4 Crore
31 May 1996
Industrial Development Bank Of India
10 Crore
14 June 2004
State Bank Of Bikaner And Jaipur
3 Crore
28 November 2003
The Catholic Syrian Bank Limited
4 Crore
21 November 2001
Export Import Bank Of India
5 Crore
16 November 2004
Indusind Bank Ltd.
3 Crore
29 August 2023
Axis Bank Limited
0
21 June 2019
Idbi Trusteeship Services Limited
0
01 May 2008
Others
0
30 October 2009
Others
0
11 December 2009
Others
0
05 October 2004
State Bank Of Patiala
0
24 March 2011
Others
0
04 January 2012
Others
0
04 March 2013
State Bank Of India
0
23 March 1999
State Bank Of Patiala
0
31 May 1996
Industrial Development Bank Of India
0
10 October 2000
State Bank Of India
0
05 September 2018
Others
0
13 November 2010
Others
0
10 March 2007
State Bank Of Indore
0
16 June 2007
Barclays Bank Plc
0
28 September 2007
Idbi Bank Limited
0
26 September 2007
State Bank Of Patiala
0
19 June 2008
Bank Of India
0
19 June 2008
Bank Of India
0
13 August 2008
Phoenix Arc Private Limited
0
31 July 2008
State Bank Of Hyderabad
0
16 July 2009
Phoenix Arc Private Limited
0
10 June 2009
Idbi Bank Limited
0
06 August 2009
Others
0
19 August 2009
Idbi Trusteeship Services Ltd.
0
24 February 2010
The Catholic Syrian Bank Limited
0
04 March 2010
Bank Of India
0
13 October 2010
Icici Bank Limited
0
25 November 2010
Bank Of Baroda
0
21 February 2011
Religare Finvest Limited
0
25 May 2011
State Bank Of Patiala
0
09 May 2011
L & T Finance Limited
0
03 October 2011
Bank Of India
0
31 March 2012
Siemens Financial Services Private Limited
0
28 March 2006
Export Import Bank Of India
0
14 March 2006
Standard Chartered Bank (being The Security Agent Acting On Behalf Of And For
0
14 June 2004
State Bank Of Bikaner And Jaipur
0
23 March 1999
State Bank Of Patiala
0
27 January 2005
Bank Of India
0
17 June 2006
Bank Of India
0
27 September 2002
Bank Of India
0
28 October 2005
State Bank Of Patiala
0
02 December 2005
Bank Of Rajasthan Limited
0
04 February 2000
State Bank Of India
0
21 November 2001
Export Import Bank Of India
0
15 January 2005
Export-import Bank Of India
0
27 June 2005
Industrial Development Bank Of India Limited
0
27 January 2005
Bank Of India
0
05 September 2018
Others
0
31 December 2004
Uti Bank Ltd.
0
28 June 2007
The Catholic Syrian Bank Limited
0
16 June 2007
Barclays Bank Plc
0
24 October 2007
Technology Development Board
0
31 July 2008
The Bank Of Rajasthan Limited
0
04 July 2008
State Bank Of Patiala
0
11 September 2008
State Bank Of India
0
26 November 2008
Idbi Bank Limited
0
16 June 2009
Edelweiss Asset Reconstruction Company Limited
0
25 August 2009
Deg - Deutsche Investitions-und Entwicklungsgesellschaft Mbh
0
02 September 2009
State Bank Of Indore
0
19 February 2010
Sicom Limited
0
04 May 2010
Edelweiss Asset Reconstruction Company Limited
0
01 July 2010
L & T Finance Limited
0
29 June 2010
State Bank Of Patiala
0
22 November 2010
State Bank Of Patiala
0
10 January 2011
Phoenix Arc Private Limited
0
30 June 2011
Canara Bank
0
25 May 2011
Sbi Global Factors Limited
0
27 August 2011
Reliance Capital Ltd
0
28 September 2011
Indiabulls Housing Finance Limited
0
24 November 2011
Edelweiss Asset Reconstruction Company Limited
0
07 June 2012
Export - Import Bank Of India
0
17 April 2013
Mahindra And Mahindra Financial Services Limited
0
28 November 2003
The Catholic Syrian Bank Limited
0
14 March 2006
State Bank Of India
0
06 January 2000
Consortium Sbi Sbop Bank Of India
0
22 August 2002
State Bank Of Patiala
0
27 October 2005
State Bank Of India
0
06 August 2001
Industrial Development Bank Of India
0
03 March 2003
State Bank Of India
0
18 March 1998
Industrial Development Corporation Of India
0
22 January 2005
The South Indian Bank Limited
0
11 September 2003
Industrial Investment Bank Of India
0
24 December 2003
Export Import Bank Of India
0
28 September 2004
Technology Devlopment Board
0
21 October 2004
State Bank Of India
0
16 November 2004
Indusind Bank Ltd.
0
31 December 2004
Axis Bank Limited
0
07 January 2005
The Cathloic Syrian Bank Ltd.
0
28 May 2005
Axis Bank Limited
0
11 March 2004
Uti Bank Ltd..
0
17 October 2006
Abn Amro Bank N. V.
0
29 August 2023
Axis Bank Limited
0
21 June 2019
Idbi Trusteeship Services Limited
0
01 May 2008
Others
0
30 October 2009
Others
0
11 December 2009
Others
0
05 October 2004
State Bank Of Patiala
0
24 March 2011
Others
0
04 January 2012
Others
0
04 March 2013
State Bank Of India
0
23 March 1999
State Bank Of Patiala
0
31 May 1996
Industrial Development Bank Of India
0
10 October 2000
State Bank Of India
0
05 September 2018
Others
0
13 November 2010
Others
0
10 March 2007
State Bank Of Indore
0
16 June 2007
Barclays Bank Plc
0
28 September 2007
Idbi Bank Limited
0
26 September 2007
State Bank Of Patiala
0
19 June 2008
Bank Of India
0
19 June 2008
Bank Of India
0
13 August 2008
Phoenix Arc Private Limited
0
31 July 2008
State Bank Of Hyderabad
0
16 July 2009
Phoenix Arc Private Limited
0
10 June 2009
Idbi Bank Limited
0
06 August 2009
Others
0
19 August 2009
Idbi Trusteeship Services Ltd.
0
24 February 2010
The Catholic Syrian Bank Limited
0
04 March 2010
Bank Of India
0
13 October 2010
Icici Bank Limited
0
25 November 2010
Bank Of Baroda
0
21 February 2011
Religare Finvest Limited
0
25 May 2011
State Bank Of Patiala
0
09 May 2011
L & T Finance Limited
0
03 October 2011
Bank Of India
0
31 March 2012
Siemens Financial Services Private Limited
0
28 March 2006
Export Import Bank Of India
0
14 March 2006
Standard Chartered Bank (being The Security Agent Acting On Behalf Of And For
0
14 June 2004
State Bank Of Bikaner And Jaipur
0
23 March 1999
State Bank Of Patiala
0
27 January 2005
Bank Of India
0
17 June 2006
Bank Of India
0
27 September 2002
Bank Of India
0
28 October 2005
State Bank Of Patiala
0
02 December 2005
Bank Of Rajasthan Limited
0
04 February 2000
State Bank Of India
0
21 November 2001
Export Import Bank Of India
0
15 January 2005
Export-import Bank Of India
0
27 June 2005
Industrial Development Bank Of India Limited
0
27 January 2005
Bank Of India
0
05 September 2018
Others
0
31 December 2004
Uti Bank Ltd.
0
28 June 2007
The Catholic Syrian Bank Limited
0
16 June 2007
Barclays Bank Plc
0
24 October 2007
Technology Development Board
0
31 July 2008
The Bank Of Rajasthan Limited
0
04 July 2008
State Bank Of Patiala
0
11 September 2008
State Bank Of India
0
26 November 2008
Idbi Bank Limited
0
16 June 2009
Edelweiss Asset Reconstruction Company Limited
0
25 August 2009
Deg - Deutsche Investitions-und Entwicklungsgesellschaft Mbh
0
02 September 2009
State Bank Of Indore
0
19 February 2010
Sicom Limited
0
04 May 2010
Edelweiss Asset Reconstruction Company Limited
0
01 July 2010
L & T Finance Limited
0
29 June 2010
State Bank Of Patiala
0
22 November 2010
State Bank Of Patiala
0
10 January 2011
Phoenix Arc Private Limited
0
30 June 2011
Canara Bank
0
25 May 2011
Sbi Global Factors Limited
0
27 August 2011
Reliance Capital Ltd
0
28 September 2011
Indiabulls Housing Finance Limited
0
24 November 2011
Edelweiss Asset Reconstruction Company Limited
0
07 June 2012
Export - Import Bank Of India
0
17 April 2013
Mahindra And Mahindra Financial Services Limited
0
28 November 2003
The Catholic Syrian Bank Limited
0
14 March 2006
State Bank Of India
0
06 January 2000
Consortium Sbi Sbop Bank Of India
0
22 August 2002
State Bank Of Patiala
0
27 October 2005
State Bank Of India
0
06 August 2001
Industrial Development Bank Of India
0
03 March 2003
State Bank Of India
0
18 March 1998
Industrial Development Corporation Of India
0
22 January 2005
The South Indian Bank Limited
0
11 September 2003
Industrial Investment Bank Of India
0
24 December 2003
Export Import Bank Of India
0
28 September 2004
Technology Devlopment Board
0
21 October 2004
State Bank Of India
0
16 November 2004
Indusind Bank Ltd.
0
31 December 2004
Axis Bank Limited
0
07 January 2005
The Cathloic Syrian Bank Ltd.
0
28 May 2005
Axis Bank Limited
0
11 March 2004
Uti Bank Ltd..
0
17 October 2006
Abn Amro Bank N. V.
0
29 August 2023
Axis Bank Limited
0
21 June 2019
Idbi Trusteeship Services Limited
0
01 May 2008
Others
0
30 October 2009
Others
0
11 December 2009
Others
0
05 October 2004
State Bank Of Patiala
0
24 March 2011
Others
0
04 January 2012
Others
0
04 March 2013
State Bank Of India
0
23 March 1999
State Bank Of Patiala
0
31 May 1996
Industrial Development Bank Of India
0
10 October 2000
State Bank Of India
0
05 September 2018
Others
0
13 November 2010
Others
0
10 March 2007
State Bank Of Indore
0
16 June 2007
Barclays Bank Plc
0
28 September 2007
Idbi Bank Limited
0
26 September 2007
State Bank Of Patiala
0
19 June 2008
Bank Of India
0
19 June 2008
Bank Of India
0
13 August 2008
Phoenix Arc Private Limited
0
31 July 2008
State Bank Of Hyderabad
0
16 July 2009
Phoenix Arc Private Limited
0
10 June 2009
Idbi Bank Limited
0
06 August 2009
Others
0
19 August 2009
Idbi Trusteeship Services Ltd.
0
24 February 2010
The Catholic Syrian Bank Limited
0
04 March 2010
Bank Of India
0
13 October 2010
Icici Bank Limited
0
25 November 2010
Bank Of Baroda
0
21 February 2011
Religare Finvest Limited
0
25 May 2011
State Bank Of Patiala
0
09 May 2011
L & T Finance Limited
0
03 October 2011
Bank Of India
0
31 March 2012
Siemens Financial Services Private Limited
0
28 March 2006
Export Import Bank Of India
0
14 March 2006
Standard Chartered Bank (being The Security Agent Acting On Behalf Of And For
0
14 June 2004
State Bank Of Bikaner And Jaipur
0
23 March 1999
State Bank Of Patiala
0
27 January 2005
Bank Of India
0
17 June 2006
Bank Of India
0
27 September 2002
Bank Of India
0
28 October 2005
State Bank Of Patiala
0
02 December 2005
Bank Of Rajasthan Limited
0
04 February 2000
State Bank Of India
0
21 November 2001
Export Import Bank Of India
0
15 January 2005
Export-import Bank Of India
0
27 June 2005
Industrial Development Bank Of India Limited
0
27 January 2005
Bank Of India
0
05 September 2018
Others
0
31 December 2004
Uti Bank Ltd.
0
28 June 2007
The Catholic Syrian Bank Limited
0
16 June 2007
Barclays Bank Plc
0
24 October 2007
Technology Development Board
0
31 July 2008
The Bank Of Rajasthan Limited
0
04 July 2008
State Bank Of Patiala
0
11 September 2008
State Bank Of India
0
26 November 2008
Idbi Bank Limited
0
16 June 2009
Edelweiss Asset Reconstruction Company Limited
0
25 August 2009
Deg - Deutsche Investitions-und Entwicklungsgesellschaft Mbh
0
02 September 2009
State Bank Of Indore
0
19 February 2010
Sicom Limited
0
04 May 2010
Edelweiss Asset Reconstruction Company Limited
0
01 July 2010
L & T Finance Limited
0
29 June 2010
State Bank Of Patiala
0
22 November 2010
State Bank Of Patiala
0
10 January 2011
Phoenix Arc Private Limited
0
30 June 2011
Canara Bank
0
25 May 2011
Sbi Global Factors Limited
0
27 August 2011
Reliance Capital Ltd
0
28 September 2011
Indiabulls Housing Finance Limited
0
24 November 2011
Edelweiss Asset Reconstruction Company Limited
0
07 June 2012
Export - Import Bank Of India
0
17 April 2013
Mahindra And Mahindra Financial Services Limited
0
28 November 2003
The Catholic Syrian Bank Limited
0
14 March 2006
State Bank Of India
0
06 January 2000
Consortium Sbi Sbop Bank Of India
0
22 August 2002
State Bank Of Patiala
0
27 October 2005
State Bank Of India
0
06 August 2001
Industrial Development Bank Of India
0
03 March 2003
State Bank Of India
0
18 March 1998
Industrial Development Corporation Of India
0
22 January 2005
The South Indian Bank Limited
0
11 September 2003
Industrial Investment Bank Of India
0
24 December 2003
Export Import Bank Of India
0
28 September 2004
Technology Devlopment Board
0
21 October 2004
State Bank Of India
0
16 November 2004
Indusind Bank Ltd.
0
31 December 2004
Axis Bank Limited
0
07 January 2005
The Cathloic Syrian Bank Ltd.
0
28 May 2005
Axis Bank Limited
0
11 March 2004
Uti Bank Ltd..
0
17 October 2006
Abn Amro Bank N. V.
0
29 August 2023
Axis Bank Limited
0
21 June 2019
Idbi Trusteeship Services Limited
0
01 May 2008
Others
0
30 October 2009
Others
0
11 December 2009
Others
0
05 October 2004
State Bank Of Patiala
0
24 March 2011
Others
0
04 January 2012
Others
0
04 March 2013
State Bank Of India
0
23 March 1999
State Bank Of Patiala
0
31 May 1996
Industrial Development Bank Of India
0
10 October 2000
State Bank Of India
0
05 September 2018
Others
0
13 November 2010
Others
0
10 March 2007
State Bank Of Indore
0
16 June 2007
Barclays Bank Plc
0
28 September 2007
Idbi Bank Limited
0
26 September 2007
State Bank Of Patiala
0
19 June 2008
Bank Of India
0
19 June 2008
Bank Of India
0
13 August 2008
Phoenix Arc Private Limited
0
31 July 2008
State Bank Of Hyderabad
0
16 July 2009
Phoenix Arc Private Limited
0
10 June 2009
Idbi Bank Limited
0
06 August 2009
Others
0
19 August 2009
Idbi Trusteeship Services Ltd.
0
24 February 2010
The Catholic Syrian Bank Limited
0
04 March 2010
Bank Of India
0
13 October 2010
Icici Bank Limited
0
25 November 2010
Bank Of Baroda
0
21 February 2011
Religare Finvest Limited
0
25 May 2011
State Bank Of Patiala
0
09 May 2011
L & T Finance Limited
0
03 October 2011
Bank Of India
0
31 March 2012
Siemens Financial Services Private Limited
0
28 March 2006
Export Import Bank Of India
0
14 March 2006
Standard Chartered Bank (being The Security Agent Acting On Behalf Of And For
0
14 June 2004
State Bank Of Bikaner And Jaipur
0
23 March 1999
State Bank Of Patiala
0
27 January 2005
Bank Of India
0
17 June 2006
Bank Of India
0
27 September 2002
Bank Of India
0
28 October 2005
State Bank Of Patiala
0
02 December 2005
Bank Of Rajasthan Limited
0
04 February 2000
State Bank Of India
0
21 November 2001
Export Import Bank Of India
0
15 January 2005
Export-import Bank Of India
0
27 June 2005
Industrial Development Bank Of India Limited
0
27 January 2005
Bank Of India
0
05 September 2018
Others
0
31 December 2004
Uti Bank Ltd.
0
28 June 2007
The Catholic Syrian Bank Limited
0
16 June 2007
Barclays Bank Plc
0
24 October 2007
Technology Development Board
0
31 July 2008
The Bank Of Rajasthan Limited
0
04 July 2008
State Bank Of Patiala
0
11 September 2008
State Bank Of India
0
26 November 2008
Idbi Bank Limited
0
16 June 2009
Edelweiss Asset Reconstruction Company Limited
0
25 August 2009
Deg - Deutsche Investitions-und Entwicklungsgesellschaft Mbh
0
02 September 2009
State Bank Of Indore
0
19 February 2010
Sicom Limited
0
04 May 2010
Edelweiss Asset Reconstruction Company Limited
0
01 July 2010
L & T Finance Limited
0
29 June 2010
State Bank Of Patiala
0
22 November 2010
State Bank Of Patiala
0
10 January 2011
Phoenix Arc Private Limited
0
30 June 2011
Canara Bank
0
25 May 2011
Sbi Global Factors Limited
0
27 August 2011
Reliance Capital Ltd
0
28 September 2011
Indiabulls Housing Finance Limited
0
24 November 2011
Edelweiss Asset Reconstruction Company Limited
0
07 June 2012
Export - Import Bank Of India
0
17 April 2013
Mahindra And Mahindra Financial Services Limited
0
28 November 2003
The Catholic Syrian Bank Limited
0
14 March 2006
State Bank Of India
0
06 January 2000
Consortium Sbi Sbop Bank Of India
0
22 August 2002
State Bank Of Patiala
0
27 October 2005
State Bank Of India
0
06 August 2001
Industrial Development Bank Of India
0
03 March 2003
State Bank Of India
0
18 March 1998
Industrial Development Corporation Of India
0
22 January 2005
The South Indian Bank Limited
0
11 September 2003
Industrial Investment Bank Of India
0
24 December 2003
Export Import Bank Of India
0
28 September 2004
Technology Devlopment Board
0
21 October 2004
State Bank Of India
0
16 November 2004
Indusind Bank Ltd.
0
31 December 2004
Axis Bank Limited
0
07 January 2005
The Cathloic Syrian Bank Ltd.
0
28 May 2005
Axis Bank Limited
0
11 March 2004
Uti Bank Ltd..
0
17 October 2006
Abn Amro Bank N. V.
0
Documents
Form DPT-3-08012021_signed
Form DPT-3-08012021_signed
Form DPT-3-07012021_signed
Letter of the charge holder stating that the amount has been satisfied-31122020
Form CHG-4-31122020
Form DPT-3-30122020-signed
Form INVESTOR COMPLAINT-29122020
Copy of MGT-8-29122020
Optional Attachment-(1)-29122020
List of share holders, debenture holders;-29122020
Identity Proof-29122020
Form MGT-7-29122020_signed
Form INVESTOR COMPLAINT-28122020
Optional Attachment-(2)-28122020
Optional Attachment-(1)-28122020
Identity Proof-28122020
Form INVESTOR COMPLAINT-27122020
Optional Attachment-(3)-27122020
Identity Proof-27122020
Optional Attachment-(2)-27122020
Optional Attachment-(1)-27122020
Form INVESTOR COMPLAINT-25122020
Identity Proof-25122020
Form INVESTOR COMPLAINT-24122020
Optional Attachment-(1)-24122020
Identity Proof-24122020
Form INVESTOR COMPLAINT-23122020
Optional Attachment-(1)-23122020
Identity Proof-23122020
Optional Attachment-(2)-23122020
